Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
A recent academic case study, published on April 22, examined using Amgen Inc's (NASDAQ:AMGN) Blincyto, a bispecific CD3xCD19 T-cell engager, to treat a patient with severe systemic sclerosis.
最近发表于4月22日的一项学术案例研究，研究了使用安进公司（纳斯达克股票代码：AMGN）Blincyto（一种双特异性CD3xCD19 T细胞结合剂）来治疗严重的系统性硬化症患者。
The findings have implications for Cullinan Therapeutics Inc's (NASDAQ:CGEM) CLN-978, a similar CD19xCD3 bispecific T-cell engager.
这些发现对库里南疗法公司（纳斯达克股票代码：CGEM）的 CLN-978 产生了影响，后者是一种类似的CD19xCD3双特异性T细胞参与者。
Most recently, Cullinan Therapeutics, formerly Cullinan Oncology, announced its plans to expand into autoimmune diseases and intends to pursue the development of CLN-978 in autoimmune diseases, with systemic lupus erythematosus (SLE) as a first indication.
最近，Cullinan Therapeutics（前身为库里南肿瘤学）宣布计划扩展到自身免疫性疾病，并打算继续在自身免疫性疾病中开发 CLN-978，将系统性红斑狼疮（SLE）作为第一适应症。
William Blair notes that the case report demonstrates that Blincyto effectively treated a patient with severe systemic sclerosis, leading to rapid B-cell depletion and symptom improvement without increasing infection risk or affecting antibody levels.
威廉·布莱尔指出，病例报告表明，Blincyto有效地治疗了严重的系统性硬化症患者，在不增加感染风险或影响抗体水平的情况下，可以快速消耗B细胞并改善症状。
This suggests the potential for using B-cell-depleting therapy in autoimmune diseases like systemic lupus erythematosus (SLE), offering easier administration than CAR-T therapy.
这表明有可能在系统性红斑狼疮（SLE）等自身免疫性疾病中使用B细胞消耗疗法，比CAR-T疗法更易于给药。
CLN-978's development will initially target SLE, with Phase 1 submission planned for the third quarter.
CLN-978 的开发最初将以系统性红斑狼疮为目标，第一阶段计划在第三季度提交。
William Blair rates Cullinan shares Outperform based on the significant potential of CLN-619 for endometrial and cervical cancer, zipalertinib for exon 20 mutant lung cancer, CLN-049 for leukemia, and CLN-978 for autoimmune diseases.
威廉·布莱尔将库里南股票评为跑赢大盘，其依据是 CLN-619 对子宫内膜癌和宫颈癌的巨大潜力，齐帕勒替尼治疗外显子 20 突变肺癌，CLN-049 用于白血病，CLN-978 用于自身免疫性疾病。
They believe the fair value of each share is $33.
他们认为每股的公允价值为33美元。
Updated data for CLN-619, expected in the second quarter of 2024, will be a key catalyst for the company, along with updates for CLN-978 in lupus and other autoimmune indications.
预计将在2024年第二季度发布的 CLN-619 更新数据以及狼疮和其他自身免疫适应症中 CLN-978 的最新数据将成为该公司的关键催化剂。
The development of Cullinan's other early-stage oncology assets would provide additional upside.
库里南其他早期肿瘤学资产的开发将提供额外的上升空间。
Earlier Wednesday, Cullinan Therapeutics announced that clinical data from its Phase 1 trial of CLN-619 in patients with advanced solid tumors will be presented at the 2024 American Society of Clinical Oncology.
周三早些时候，Cullinan Therapeutics宣布，其针对晚期实体瘤患者的 CLN-619 1期试验的临床数据将在2024年美国临床肿瘤学会上公布。
The data will include the first results from the dose escalation cohort of CLN-619 in combination with checkpoint inhibitor pembrolizumab and updated results from the monotherapy dose-escalation cohort in patients with advanced solid tumors.
这些数据将包括 CLN-619 与检查点抑制剂pembrolizumab联合使用剂量递增队列的初步结果，以及晚期实体瘤患者单一疗法剂量递增队列的最新结果。
Price Action: CGEM shares are up 15.10% at $19.18 at the last check Wednesday.
价格走势：在周三的最后一次检查中，CGEM股价上涨15.10％，至19.18美元。
Photo via PublicDomainPictures from Pixabay
照片通过 来自 Pixabay 的公共域名图片